logo

For the Inventor, By the Inventor

San Diego, CA, United States of America

Amylin Pharmaceuticals, Inc.

Calculating rank
USPTO Granted Patents = 164

% Expired Patents = 55.5



Trademarks = 4

Forward Citations = 4,975

Loading Chart...
Loading Chart...

155 inventors (with patents filed for the assignee):

goldMedal Andrew A Young (53 out of 68 patents)

silverMedal Kathryn Susan Prickett (37 out of 38 patents)

bronzeMedal Soumitra S Ghosh (21 out of 59 patents)

4.  David Geoffrey Parkes (20 out of 21 patents)

5.  Christine Marie Mack (16 out of 17 patents)

6.  Nigel Robert Arnold Beeley (15 out of 16 patents)

7.  Odile Esther Levy (14 out of 29 patents)

8.  Christopher Joseph Soares (13 out of 23 patents)

9.  Bronislava Gedulin (13 out of 26 patents)

10.  Carolyn M Jodka (13 out of 14 patents)

11.  Lawrence J D'Souza (13 out of 14 patents)

12.  Michael R Hanley (12 out of 26 patents)

13.  Richard A Pittner (11 out of 11 patents)

14.  Thomas R Coolidge (11 out of 23 patents)

15.  Orville G Kolterman (11 out of 11 patents)


Core Competencies:
GLP-1 Receptor Agonists
Engineered Polypeptides
Drug Delivery Devices
Amylin Agonists
Sustained Release
Hybrid Polypeptides
Exendin Peptides
Obesity Treatment
Peptide Conjugates
Cholesterol Reduction
Pancreatic Polypeptides
Cardiac Arrhythmias

164 patents:

1. 9884092 - Methods for treating diabetes and reducing body weight (2018-02-06),
2. 9593154 - Engineered polypeptides having enhanced duration of action (2017-03-14),
3. 9453063 - Hybrid polypeptides with selectable properties (2016-09-27),
4. 9382304 - Engineered polypeptides having enhanced duration of action with reduced immunogenicity (2016-07-05),
5. 9249181 - C-terminal amidation of polypeptides (2016-02-02),
6. 9248240 - Formulation delivery device (2016-02-02),
7. 9238076 - Polymer-based sustained release device (2016-01-19),
8. 9217022 - GLP-1 receptor agonist compounds having stabilized regions (2015-12-22),
9. 9161953 - GLP-1 receptor agonists for islet cell transplantation (2015-10-20),
10. 9133260 - GIP analog and hybrid polypeptides with selectable properties (2015-09-15),
11. 9034819 - Method of lowering cholesterol and triglycerides by administering exendins (2015-05-19),
12. 8951962 - Modified exendins and exendin agonists (2015-02-10),
13. 8946149 - Use of exendin and analogs thereof to delay or prevent cardiac remodeling (2015-02-03),
14. 8927687 - Microcrystalline Y receptor agonists (2015-01-06),
15. 8906851 - Method for treating diabetes (2014-12-09),
Company Overview
Amylin Pharmaceuticals, Inc., based in San Diego, CA, specializes in the development of innovative therapies for diabetes management. The company focuses on GLP-1 receptor agonists and engineered polypeptides, aiming to enhance treatment efficacy through advanced drug delivery systems. Their research encompasses sustained release formulations and hybrid polypeptides, addressing both diabetes and obesity. Amylin is committed to improving patient outcomes through cutting-edge technology and a deep understanding of metabolic disorders.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Nov 3 2026

Amylin Pharmaceuticals, Inc. USPTO Patent Assignee Logo
164 Patents

#32 in San Diego, CA

#530 in California

#2,425 in US

#5,038 in the World

San Diego, CA (US)
San Diego, CA, United States of America

Amylin Pharmaceuticals, Inc.

Forward Citations = 4,975

155 inventors:

goldMedal Andrew A Young (53 out of 68 patents)

silverMedal Kathryn Susan Prickett (37 out of 38 patents)

bronzeMedal Soumitra S Ghosh (21 out of 59 patents)

4.  David Geoffrey Parkes (20 out of 21 patents)

5.  Christine Marie Mack (16 out of 17 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Amylin Pharmaceuticals, Inc.. Retrieved from https://idiyas.com/company/amylin-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…